WallabyPhenox has today announced that the first patient has been enrolled in PROMISE—an investigator-initiated, prospective study examining how medium-vessel occlusion (MeVO) acute ischaemic strokes are managed within 24 hours of symptom onset. The first subject was enrolled at Indiana University Health Methodist Hospital (Indianapolis, USA).
According to WallabyPhenox, PROMISE is designed to capture real-world practice across participating US sites, and help characterise the current “equipoise”—between mechanical thrombectomy and medical management—among treating physicians.
To this end, the study is enrolling patients managed with mechanical thrombectomy as well as those treated medically, and will follow their outcomes over the course of six months. PROMISE plans to enrol patients across 30 participating US sites.
“Management for MeVO-related stroke is one of the next frontiers in advancing care for stroke patients,” commented Kaustubh Limaye (Indiana University Medical Center, Indianapolis, USA), global principal investigator for PROMISE. “We planned this study to better understand the practice and challenges involved in management of these patients in a prospective, unbiased way. To achieve a higher level of nuanced understanding, we planned the imaging to be core lab adjudicated. I thank WallabyPhenox for their support to this investigator-initiated project.”
“This important study is expected to help answer a critical clinical question: whether revascularisation attempt benefits patients with MeVO,” added Devi Patra, who is a study co-lead alongside Ann Jones at Indiana University. “Current evidence remains largely equivocal, underscoring the need for clearer data to guide treatment decisions.”
“This study is important because it includes all MeVO patients; not just those treated endovascularly,” said Michael Froehler (Vanderbilt University Medical Center, Nashville, USA). “The results will help us to understand real-world MeVO outcomes.”
WallabyPhenox is supporting PROMISE as part of its commitment to advancing the evidence base behind stroke care, as stated by the company in today’s press release.
“Reaching first enrolment in PROMISE reflects WallabyPhenox’s commitment to advancing the science behind stroke care—not just the tools that support it,” said Ruilin Zhao, the company’s chief executive officer (CEO). “We’re proud to stand behind Dr Limaye and the investigators as they generate the evidence the neurovascular community needs to make the best possible decisions for MeVO patients.”
